Drugs 🔻 ) (




## Utomilumab

This drug entry is a **stub** and has not been fully annotated. It is scheduled to be annotated soon.

DENTIFICATION			
Name	Utomilumab		
Accession Number	DB15113		
Туре	Biotech		
Groups	Investigational		
Description	Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).		
Synonyms	PF-05082566		
Categories	Amino Acids, Peptides, and Proteins  Antibodies  Blood Proteins	Globulins  Immunoglobulin Isotypes  Immunoglobulins	Immunoproteins  Proteins  Serum Globulins
UNII	6YY80697VF		

## PHARMACOLOGY

Indication	Not Available
Pharmacodynamics	Not Available
Mechanism of action	Not Available
Absorption	Not Available
Volume of distribution	Not Available
Protein binding	Not Available
Metabolism	Not Available
Route of elimination	Not Available



PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓ Lymphoma (FL) / Lung Cancer Non-Small Cell Cancer (NSCLC)

> Follicular Lymphoma (FL) 1 Not Yet Treatment 1 Recruiting Recruiting Treatment CCND1 Positive / CD20 Positive / Recurrent Diffuse Large B-Cell 1 Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory <u>Diffuse Large B Cell Lymphoma</u> / <u>Refractory Mantle Cell</u> <u>Lymphoma</u> / <u>Transformed Follicular Lymphoma to Diffuse Large</u> **B-Cell Lymphoma** Recruiting Treatment COL6A3 Positive / HLA-A\*0201 Positive Cells Present / Platinum 1 Resistant Ovarian Cancer / PRAME Positive / Recurrent Ovarian Carcinoma Recruiting Treatment <u>Colorectal Cancers</u> / <u>Malignant Neoplasms of Digestive Organs</u> / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8 HER2 Positive Breast Carcinoma / Recurrent Breast Carcinoma / Recruiting Treatment Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer Advanced/Metastatic Solid Tumors Terminated Treatment 1 Advanced Malignant Solid Neoplasm / Castration-Resistant Recruiting 1, 2 Treatment 1 Prostate Carcinoma / Malignant Neoplasm of Breast / Malignant Neoplasms of Bone and Articular Cartilage / Malignant Neoplasms of Digestive Organs / Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Male Genital Organs / Malignant Neoplasms of Mesothelial and Soft <u>Tissue</u> / <u>Malignant Neoplasms of Respiratory and Intrathoracic</u> Organs / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract / Malignant Solid Neoplasm / Metastatic Hormone Refractory Prostate Cancer / Metastatic Malignant Solid Neoplasm / Neoplasms of Uncertain or Unknown Behavior / Neoplasms, Malignant / Prostate

> > Carcinoma Metastatic in the Bone / Refractory Malignant Solid Neoplasm / Stage IV Prostate Cancer AJCC v8 / Stage IVA Prostate

Cancer AJCC v8 / Stage IVB Prostate Cancer AJCC v8

Refractory Large B-cell Lymphoma

Drugs

Showing 1 to 10 of 15 entries

Recruiting Treatment

1, 2

<u>2</u> > 1

1

## **PHARMACOECONOMICS**

Manufacturers	Not Available
Packagers	Not Available
Dosage forms	Not Available
Prices	Not Available
Patents	Not Available

## **PROPERTIES**

Not Available State

**Experimental** 

Not Available

**Properties** https://www.drugbank.ca/drugs/DB15113 7/25/2019 Utomilumab - DrugBank

TAXONOMY

Drugs 

Q

Drug created on May 20, 2019 08:50 / Updated on May 21, 2019 12:35

Not classified



About Support

About DrugBank FAQ

DrugBank Blog Help Center

<u>Wishart Research Group</u> <u>Email Support</u>

<u>Careers</u>


Terms of Use

Classification

<u>Privacy Policy</u>








This project is supported April the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Data Licenses Metabolomics Innovation Centre (Twic), a nationally-funded research and core facility that supported wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc.









**Genome**BritishColumbia

https://www.drugbank.ca/drugs/DB15113